مصطلحات الفهرس: male, malignant neoplasm/dt [Drug Therapy], medication compliance, medication error, medication therapy management, metastasis/dt [Drug Therapy], multiple cycle treatment, multiple myeloma/dt [Drug Therapy], pneumocystosis/dt [Drug Therapy], pneumocystosis/pc [Prevention], potentially inappropriate medication, quality control, randomized controlled trial (topic), review, solid malignant neoplasm/dt [Drug Therapy], stomach cancer/dt [Drug Therapy], systematic review, teleconsultation, thrombosis prevention, venous thromboembolism/dt [Drug Therapy], venous thromboembolism/pc [Prevention], abiraterone/dt [Drug Therapy], abiraterone/pv [Special Situation for Pharmacovigilance], antiemetic agent/ae [Adverse Drug Reaction], antiemetic agent/dt [Drug Therapy], antifungal agent/dt [Drug Therapy], antiinfective agent, antineoplastic agent/ae [Adverse Drug Reaction], antineoplastic agent/ct [Clinical Trial], antineoplastic agent/do [Drug Dose], antineoplastic agent/dt [Drug Therapy], antineoplastic agent/iv [Intravenous Drug Administration], antineoplastic agent/po [Oral Drug Administration], antineoplastic agent/pa [Parenteral Drug Administration], antineoplastic agent/pv [Special Situation for Pharmacovigilance], antithrombocytic agent/dt [Drug Therapy], bicalutamide/dt [Drug Therapy], bicalutamide/pv [Special Situation for Pharmacovigilance], bisphosphonic acid derivative, calcium, corticosteroid, dexamethasone/pv [Special Situation for Pharmacovigilance], enzalutamide/dt [Drug Therapy], enzalutamide/pv [Special Situation for Pharmacovigilance], erlotinib/pv [Special Situation for Pharmacovigilance], gefitinib/pv [Special Situation for Pharmacovigilance], gimeracil plus oteracil potassium plus tegafur/dt [Drug Therapy], gimeracil plus oteracil potassium plus tegafur/pv [Special Situation for Pharmacovigilance], influenza vaccine, ondansetron/pv [Special Situation for Pharmacovigilance], vitamin D, drug choice, adjuvant chemotherapy, adjuvant therapy, adult, adverse drug reaction/si [Side Effect], aged, antibiotic prophylaxis, cancer chemotherapy, cancer immunotherapy, cancer palliative therapy, castration resistant prostate cancer/dt [Drug Therapy], chemotherapy induced nausea and vomiting/dt [Drug Therapy], chemotherapy induced nausea and vomiting/si [Side Effect], clinical pharmacy, controlled study, corticosteroid therapy, drug interaction, female, follow up, health care planning, human, influenza vaccination, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28684Test
Journal of Pharmacy Practice and Research
Click here for full text options
LibKey Link

مصطلحات الفهرس: male, malignant neoplasm/dt [Drug Therapy], medication compliance, medication error, medication therapy management, metastasis/dt [Drug Therapy], multiple cycle treatment, multiple myeloma/dt [Drug Therapy], pneumocystosis/dt [Drug Therapy], pneumocystosis/pc [Prevention], potentially inappropriate medication, quality control, randomized controlled trial (topic), review, solid malignant neoplasm/dt [Drug Therapy], stomach cancer/dt [Drug Therapy], systematic review, teleconsultation, thrombosis prevention, venous thromboembolism/dt [Drug Therapy], venous thromboembolism/pc [Prevention], abiraterone/dt [Drug Therapy], abiraterone/pv [Special Situation for Pharmacovigilance], antiemetic agent/ae [Adverse Drug Reaction], antiemetic agent/dt [Drug Therapy], antifungal agent/dt [Drug Therapy], antiinfective agent, antineoplastic agent/ae [Adverse Drug Reaction], antineoplastic agent/ct [Clinical Trial], antineoplastic agent/do [Drug Dose], antineoplastic agent/dt [Drug Therapy], antineoplastic agent/iv [Intravenous Drug Administration], antineoplastic agent/po [Oral Drug Administration], antineoplastic agent/pa [Parenteral Drug Administration], antineoplastic agent/pv [Special Situation for Pharmacovigilance], antithrombocytic agent/dt [Drug Therapy], bicalutamide/dt [Drug Therapy], bicalutamide/pv [Special Situation for Pharmacovigilance], bisphosphonic acid derivative, calcium, corticosteroid, dexamethasone/pv [Special Situation for Pharmacovigilance], enzalutamide/dt [Drug Therapy], enzalutamide/pv [Special Situation for Pharmacovigilance], erlotinib/pv [Special Situation for Pharmacovigilance], gefitinib/pv [Special Situation for Pharmacovigilance], gimeracil plus oteracil potassium plus tegafur/dt [Drug Therapy], gimeracil plus oteracil potassium plus tegafur/pv [Special Situation for Pharmacovigilance], influenza vaccine, ondansetron/pv [Special Situation for Pharmacovigilance], vitamin D, drug choice, adjuvant chemotherapy, adjuvant therapy, adult, adverse drug reaction/si [Side Effect], aged, antibiotic prophylaxis, cancer chemotherapy, cancer immunotherapy, cancer palliative therapy, castration resistant prostate cancer/dt [Drug Therapy], chemotherapy induced nausea and vomiting/dt [Drug Therapy], chemotherapy induced nausea and vomiting/si [Side Effect], clinical pharmacy, controlled study, corticosteroid therapy, drug interaction, female, follow up, health care planning, human, influenza vaccination, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28684Test
Journal of Pharmacy Practice and Research
LibKey Link

مصطلحات الفهرس: hypercalcemia/si [Side Effect], hyperglycemia/si [Side Effect], hypertransaminasemia/si [Side Effect], hypokalemia/si [Side Effect], hyponatremia/si [Side Effect], liver cell carcinoma/dt [Drug Therapy], loss of appetite/si [Side Effect], lower respiratory tract infection/si [Side Effect], lung embolism/si [Side Effect], major clinical study, male, maximum tolerated dose, melanoma/dt [Drug Therapy], merkel cell carcinoma/dt [Drug Therapy], microsatellite instability, monotherapy, multiple cycle treatment, nausea and vomiting/si [Side Effect], non small cell lung cancer/dt [Drug Therapy], optimal drug dose, ovary carcinoma/dt [Drug Therapy], pancreas cancer/dt [Drug Therapy], phase 1 clinical trial, pleura effusion/si [Side Effect], pneumonia/si [Side Effect], priority journal, rash/si [Side Effect], recommended drug dose, renal cell carcinoma/dt [Drug Therapy], retrospective study, sepsis/si [Side Effect], skin carcinoma/dt [Drug Therapy], small intestine obstruction/si [Side Effect], solid malignant neoplasm/dt [Drug Therapy], stomach cancer/dt [Drug Therapy], time to maximum plasma concentration, treatment response time, triple negative breast cancer/dt [Drug Therapy], upper gastrointestinal bleeding/si [Side Effect], bilirubin/ec [Endogenous Compound], new drug/ct [Clinical Trial], new drug/do [Drug Dose], new drug/dt [Drug Therapy], new drug/to [Drug Toxicity], new drug/iv [Intravenous Drug Administration], new drug/pk [Pharmacokinetics], new drug/pv [Special Situation for Pharmacovigilance], programmed death 1 ligand 1/ec [Endogenous Compound], tislelizumab/ae [Adverse Drug Reaction], tislelizumab/ct [Clinical Trial], tislelizumab/cr [Drug Concentration], tislelizumab/do [Drug Dose], tislelizumab/dt [Drug Therapy], tislelizumab/to [Drug Toxicity], tislelizumab/iv [Intravenous Drug Administration], tislelizumab/pk [Pharmacokinetics], tislelizumab/pv [Special Situation for Pharmacovigilance], tislelizumab/tm [Unexpected Outcome of Drug Treatment], immunohistochemical test kit, VENTANA PD-L1 (SP263), maximum concentration, adult, aged, anemia/si [Side Effect], antineoplastic activity, area under the curve, article, ascites/si [Side Effect], backache/si [Side Effect], bile duct carcinoma/dt [Drug Therapy], body weight disorder/si [Side Effect], clinical outcome, cohort analysis, colitis/si [Side Effect], colorectal cancer/dt [Drug Therapy], constipation/si [Side Effect], controlled study, coughing/si [Side Effect], diarrhea/si [Side Effect], drug dosage form comparison, drug dose escalation, drug dose regimen, drug efficacy, drug half life, drug safety, drug tolerability, drug withdrawal, dysphagia/si [Side Effect], dyspnea/si [Side Effect], esophagus cancer/dt [Drug Therapy], esophagus carcinoma/dt [Drug Therapy], fatigue/si [Side Effect], female, follow up, gastrointestinal stromal tumor/dt [Drug Therapy], head and neck squamous cell carcinoma/dt [Drug Therapy], human, hyperbilirubinemia/si [Side Effect], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29145Test
Journal for ImmunoTherapy of Cancer
Click here for full text options
LibKey Link

مصطلحات الفهرس: chemotherapy induced nausea and vomiting/dt [Drug Therapy], chemotherapy induced nausea and vomiting/pc [Prevention], colorectal cancer/dt [Drug Therapy], constipation/si [Side Effect], disease severity, drug use, fatigue/si [Side Effect], headache/si [Side Effect], human, meta analysis, review, systematic review, treatment duration, treatment response, dexamethasone/ae [Adverse Drug Reaction], dexamethasone/cb [Drug Combination], dexamethasone/dt [Drug Therapy], granisetron/cb [Drug Combination], granisetron/dt [Drug Therapy], irinotecan/dt [Drug Therapy], stomach cancer/dt [Drug Therapy], advanced cancer/dt [Drug Therapy], adverse event, anorexia/si [Side Effect], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29167Test
Critical Reviews in Oncology/Hematology
Click here for full text options
LibKey Link

مصطلحات الفهرس: stomach cancer/rt [Radiotherapy], stomach cancer/su [Surgery], bevacizumab/ct [Clinical Trial], bevacizumab/dt [Drug Therapy], capecitabine/ct [Clinical Trial], capecitabine/cb [Drug Combination], capecitabine/dt [Drug Therapy], carboplatin/ct [Clinical Trial], carboplatin/cb [Drug Combination], carboplatin/dt [Drug Therapy], cisplatin/ct [Clinical Trial], cisplatin/cb [Drug Combination], cisplatin/dt [Drug Therapy], docetaxel/ct [Clinical Trial], docetaxel/cb [Drug Combination], docetaxel/dt [Drug Therapy], epirubicin/ct [Clinical Trial], epirubicin/cb [Drug Combination], epirubicin/dt [Drug Therapy], fluorouracil/ct [Clinical Trial], fluorouracil/cb [Drug Combination], fluorouracil/dt [Drug Therapy], gimeracil plus oteracil potassium plus tegafur/ct [Clinical Trial], gimeracil plus oteracil potassium plus tegafur/cb [Drug Combination], gimeracil plus oteracil potassium plus tegafur/dt [Drug Therapy], oxaliplatin/ct [Clinical Trial], oxaliplatin/cb [Drug Combination], paclitaxel/ct [Clinical Trial], paclitaxel/cb [Drug Combination], paclitaxel/dt [Drug Therapy], vinorelbine tartrate/ct [Clinical Trial], vinorelbine tartrate/cb [Drug Combination], vinorelbine tartrate/dt [Drug Therapy], gastroesophageal cancer/dt [Drug Therapy], gastroesophageal cancer/rt [Radiotherapy], gastroesophageal cancer/su [Surgery], oxaliplatin/dt [Drug Therapy], cancer adjuvant therapy, cancer immunotherapy, cancer staging, cancer surgery, chemoradiotherapy, computer assisted tomography, endoscopic ultrasonography, esophageal squamous cell carcinoma/rt [Radiotherapy], esophageal squamous cell carcinoma/su [Surgery], esophagus cancer/dt [Drug Therapy], esophagus cancer/rt [Radiotherapy], esophagus cancer/su [Surgery], external beam radiotherapy, geography, human, multimodality cancer therapy, multiple cycle treatment, outcome assessment, overall survival, patient care, patient selection, perioperative period, review, stomach cancer/dt [Drug Therapy], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28901Test
Expert Review of Anticancer Therapy
Click here for full text options
LibKey Link

مصطلحات الفهرس: hypercalcemia/si [Side Effect], hyperglycemia/si [Side Effect], hypertransaminasemia/si [Side Effect], hypokalemia/si [Side Effect], hyponatremia/si [Side Effect], liver cell carcinoma/dt [Drug Therapy], loss of appetite/si [Side Effect], lower respiratory tract infection/si [Side Effect], lung embolism/si [Side Effect], major clinical study, male, maximum tolerated dose, melanoma/dt [Drug Therapy], merkel cell carcinoma/dt [Drug Therapy], microsatellite instability, monotherapy, multiple cycle treatment, nausea and vomiting/si [Side Effect], non small cell lung cancer/dt [Drug Therapy], optimal drug dose, ovary carcinoma/dt [Drug Therapy], pancreas cancer/dt [Drug Therapy], phase 1 clinical trial, pleura effusion/si [Side Effect], pneumonia/si [Side Effect], priority journal, rash/si [Side Effect], recommended drug dose, renal cell carcinoma/dt [Drug Therapy], retrospective study, sepsis/si [Side Effect], skin carcinoma/dt [Drug Therapy], small intestine obstruction/si [Side Effect], solid malignant neoplasm/dt [Drug Therapy], stomach cancer/dt [Drug Therapy], time to maximum plasma concentration, treatment response time, triple negative breast cancer/dt [Drug Therapy], upper gastrointestinal bleeding/si [Side Effect], bilirubin/ec [Endogenous Compound], new drug/ct [Clinical Trial], new drug/do [Drug Dose], new drug/dt [Drug Therapy], new drug/to [Drug Toxicity], new drug/iv [Intravenous Drug Administration], new drug/pk [Pharmacokinetics], new drug/pv [Special Situation for Pharmacovigilance], programmed death 1 ligand 1/ec [Endogenous Compound], tislelizumab/ae [Adverse Drug Reaction], tislelizumab/ct [Clinical Trial], tislelizumab/cr [Drug Concentration], tislelizumab/do [Drug Dose], tislelizumab/dt [Drug Therapy], tislelizumab/to [Drug Toxicity], tislelizumab/iv [Intravenous Drug Administration], tislelizumab/pk [Pharmacokinetics], tislelizumab/pv [Special Situation for Pharmacovigilance], tislelizumab/tm [Unexpected Outcome of Drug Treatment], immunohistochemical test kit, VENTANA PD-L1 (SP263), maximum concentration, adult, aged, anemia/si [Side Effect], antineoplastic activity, area under the curve, article, ascites/si [Side Effect], backache/si [Side Effect], bile duct carcinoma/dt [Drug Therapy], body weight disorder/si [Side Effect], clinical outcome, cohort analysis, colitis/si [Side Effect], colorectal cancer/dt [Drug Therapy], constipation/si [Side Effect], controlled study, coughing/si [Side Effect], diarrhea/si [Side Effect], drug dosage form comparison, drug dose escalation, drug dose regimen, drug efficacy, drug half life, drug safety, drug tolerability, drug withdrawal, dysphagia/si [Side Effect], dyspnea/si [Side Effect], esophagus cancer/dt [Drug Therapy], esophagus carcinoma/dt [Drug Therapy], fatigue/si [Side Effect], female, follow up, gastrointestinal stromal tumor/dt [Drug Therapy], head and neck squamous cell carcinoma/dt [Drug Therapy], human, hyperbilirubinemia/si [Side Effect], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29145Test
Journal for ImmunoTherapy of Cancer
LibKey Link

مصطلحات الفهرس: chemotherapy induced nausea and vomiting/dt [Drug Therapy], chemotherapy induced nausea and vomiting/pc [Prevention], colorectal cancer/dt [Drug Therapy], constipation/si [Side Effect], disease severity, drug use, fatigue/si [Side Effect], headache/si [Side Effect], human, meta analysis, review, systematic review, treatment duration, treatment response, dexamethasone/ae [Adverse Drug Reaction], dexamethasone/cb [Drug Combination], dexamethasone/dt [Drug Therapy], granisetron/cb [Drug Combination], granisetron/dt [Drug Therapy], irinotecan/dt [Drug Therapy], stomach cancer/dt [Drug Therapy], advanced cancer/dt [Drug Therapy], adverse event, anorexia/si [Side Effect], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29167Test
Critical Reviews in Oncology/Hematology
LibKey Link

مصطلحات الفهرس: stomach cancer/rt [Radiotherapy], stomach cancer/su [Surgery], bevacizumab/ct [Clinical Trial], bevacizumab/dt [Drug Therapy], capecitabine/ct [Clinical Trial], capecitabine/cb [Drug Combination], capecitabine/dt [Drug Therapy], carboplatin/ct [Clinical Trial], carboplatin/cb [Drug Combination], carboplatin/dt [Drug Therapy], cisplatin/ct [Clinical Trial], cisplatin/cb [Drug Combination], cisplatin/dt [Drug Therapy], docetaxel/ct [Clinical Trial], docetaxel/cb [Drug Combination], docetaxel/dt [Drug Therapy], epirubicin/ct [Clinical Trial], epirubicin/cb [Drug Combination], epirubicin/dt [Drug Therapy], fluorouracil/ct [Clinical Trial], fluorouracil/cb [Drug Combination], fluorouracil/dt [Drug Therapy], gimeracil plus oteracil potassium plus tegafur/ct [Clinical Trial], gimeracil plus oteracil potassium plus tegafur/cb [Drug Combination], gimeracil plus oteracil potassium plus tegafur/dt [Drug Therapy], oxaliplatin/ct [Clinical Trial], oxaliplatin/cb [Drug Combination], paclitaxel/ct [Clinical Trial], paclitaxel/cb [Drug Combination], paclitaxel/dt [Drug Therapy], vinorelbine tartrate/ct [Clinical Trial], vinorelbine tartrate/cb [Drug Combination], vinorelbine tartrate/dt [Drug Therapy], gastroesophageal cancer/dt [Drug Therapy], gastroesophageal cancer/rt [Radiotherapy], gastroesophageal cancer/su [Surgery], oxaliplatin/dt [Drug Therapy], cancer adjuvant therapy, cancer immunotherapy, cancer staging, cancer surgery, chemoradiotherapy, computer assisted tomography, endoscopic ultrasonography, esophageal squamous cell carcinoma/rt [Radiotherapy], esophageal squamous cell carcinoma/su [Surgery], esophagus cancer/dt [Drug Therapy], esophagus cancer/rt [Radiotherapy], esophagus cancer/su [Surgery], external beam radiotherapy, geography, human, multimodality cancer therapy, multiple cycle treatment, outcome assessment, overall survival, patient care, patient selection, perioperative period, review, stomach cancer/dt [Drug Therapy], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28901Test
Expert Review of Anticancer Therapy
LibKey Link

مصطلحات الفهرس: genetic parameters, human, microsatellite instability, molecular diagnosis, oncogene, oncogene K ras, oncogene N ras, personalized medicine, prediction, review, stomach cancer/di [Diagnosis], stomach cancer/dt [Drug Therapy], stomach cancer/et [Etiology], tumor suppressor gene, bevacizumab/dt [Drug Therapy], biological marker/ec [Endogenous Compound], cetuximab/dt [Drug Therapy], fluorouracil/dt [Drug Therapy], irinotecan/dt [Drug Therapy], messenger RNA/ec [Endogenous Compound], pembrolizumab/dt [Drug Therapy], ramucirumab/dt [Drug Therapy], trastuzumab/dt [Drug Therapy], vemurafenib/dt [Drug Therapy], microsatellite stability, PTEN gene, TP53 gene, colorectal cancer/di [Diagnosis], cancer chemotherapy, cancer classification, cancer immunotherapy, cancer patient, cancer prognosis, cancer survival, cancer therapy, carcinogenesis, clinical practice, colorectal cancer/dt [Drug Therapy], colorectal cancer/et [Etiology], disease association, drug research, epithelial mesenchymal transition, gene expression, gene expression profiling, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35769Test
Cancer Treatment Reviews
Click here for full text options
LibKey Link

مصطلحات الفهرس: genetic parameters, human, microsatellite instability, molecular diagnosis, oncogene, oncogene K ras, oncogene N ras, personalized medicine, prediction, review, stomach cancer/di [Diagnosis], stomach cancer/dt [Drug Therapy], stomach cancer/et [Etiology], tumor suppressor gene, bevacizumab/dt [Drug Therapy], biological marker/ec [Endogenous Compound], cetuximab/dt [Drug Therapy], fluorouracil/dt [Drug Therapy], irinotecan/dt [Drug Therapy], messenger RNA/ec [Endogenous Compound], pembrolizumab/dt [Drug Therapy], ramucirumab/dt [Drug Therapy], trastuzumab/dt [Drug Therapy], vemurafenib/dt [Drug Therapy], microsatellite stability, PTEN gene, TP53 gene, colorectal cancer/di [Diagnosis], cancer chemotherapy, cancer classification, cancer immunotherapy, cancer patient, cancer prognosis, cancer survival, cancer therapy, carcinogenesis, clinical practice, colorectal cancer/dt [Drug Therapy], colorectal cancer/et [Etiology], disease association, drug research, epithelial mesenchymal transition, gene expression, gene expression profiling, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35769Test
Cancer Treatment Reviews
LibKey Link